Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation
[DE] VERWENDUNG VON XANTHINDERIVATEN ZUR REDUKTION DER PATHOLOGISCHEN HYPERREAGIBILITÄT EOSINOPHILER GRANULOZYTEN, NEUE XANTHINVERBINDUNGEN UND VERFAHREN ZU DEREN HERSTELLUNG<br/>[EN] USE OF XANTHINE DERIVATIVES FOR REDUCING THE PATHOLOGICAL HYPER-REACTIVITY OF EOSINOPHILIC GRANULOCYTES, NOVEL XANTHINE COMPOUNDS AND PROCESS FOR PRODUCING THEM<br/>[FR] UTILISATION DE DERIVES DE XANTHINE POUR REDUIRE L'HYPERREACTIVITE PATHOLOGIQUE DE GRANULOCYTES EOSINOPHILES, NOUVEAUX COMPOSES A BASE DE XANTHINE ET PROCEDE DE PRODUCTION DE CES DERNIERS
申请人:HOECHST AKTIENGESELLSCHAFT
公开号:WO1995026727A1
公开(公告)日:1995-10-12
(DE) Tertiäre 1-(Hydroxyalkyl)-4-alkylxanthine eignen sich zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, die mit einer pathologisch gesteigerten Reagibilität eosinophiler Granulozyten verbunden ist. Es werden neue Xanthinderivaten beschrieben und Verfahren zu deren Herstellung.(EN) Tertiary 1-(hydroxy alkyl)-4-alkyl xanthines are suitable for the preparation of medicaments for the treatment of diseases connected with a pathologically raised reactivity of eosinophilic granulocytes. The description relates to novel xanthine derivatives and to a process for producing them.(FR) Les 1-(hydroxyalkyle)-4-alkylxanthines tertiaires conviennent à la préparation de médicaments pour le traitement de maladies liées à la réactivité pathologiquement accrue des granulocytes éosinophiles. L'invention porte sur de nouveaux dérivés de xanthine et sur leur procédé de production.
VERWENDUNG VON XANTHINDERIVATEN ZUR REDUKTION DER PATHOLOGISCHEN HYPERREAGIBILITÄT EOSINOPHILER GRANULOZYTEN, NEUE XANTHINVERBINDUNGEN UND VERFAHREN ZU DEREN HERSTELLUNG
申请人:HOECHST AKTIENGESELLSCHAFT
公开号:EP0758239A1
公开(公告)日:1997-02-19
Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation
申请人:Hoechst Aktiengesellschaft
公开号:US20020010333A1
公开(公告)日:2002-01-24
Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation.
Tertiary 1-(hydroxyalkyl)-4-alkylxanthines are suitable for the production of pharmaceuticals for the treatment of disorders which is associated with a pathologically increased reactivity of eosinophilic granulocytes. Novel xanthine derivatives and process for their preparation are described.